Literature DB >> 27060021

Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies.

Stefano Marventano1, Federico Salomone2, Justyna Godos3, Francesca Pluchinotta4, Daniele Del Rio5, Antonio Mistretta1, Giuseppe Grosso6.   

Abstract

BACKGROUND & AIMS: Diet plays a role in the onset and progression of metabolic disorders, including non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS). We aimed to systematically review and perform quantitative analyses of results from observational studies on coffee/tea consumption and NAFLD or MetS.
METHODS: A Medline and Embase search was performed to retrieve articles published up to March 2015. We used a combination of the keywords "coffee", "caffeine", "tea", "non-alcoholic fatty liver disease", "non-alcoholic steatohepatitis", "metabolic syndrome". Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated by random-effects model.
RESULTS: Seven studies assessed coffee consumption in NAFLD patients. Fibrosis scores were reported in four out of seven; all four studies revealed an inverse association of coffee intake with fibrosis severity, although the lack of comparable exposure and outcomes did not allow to perform pooled analysis. Seven studies met the inclusion criteria to be included in the meta-analysis on coffee consumption and MetS. Individuals consuming higher quantities of coffee were less like to have MetS (RR = 0.87, 95% CI: 0.79-0.96). However, the association of coffee and individual components of MetS was not consistent across the studies. Pooled analysis of six studies exploring the association between tea consumption and MetS resulted in decreased odds of MetS for individuals consuming more tea (RR = 0.83, 95% CI: 0.73-0.95).
CONCLUSIONS: Studies on coffee and NAFLD suggest that coffee consumption could have a protective role on fibrosis. Both coffee and tea consumption are associated with less likelihood of having MetS but further research with better designed studies is needed.
Copyright © 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Coffee; Meta-analysis; Metabolic syndrome; NAFLD; Tea

Mesh:

Substances:

Year:  2016        PMID: 27060021     DOI: 10.1016/j.clnu.2016.03.012

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  50 in total

1.  Principles of pharmacological research of nutraceuticals.

Authors:  Ruth Andrew; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2017-06       Impact factor: 8.739

2.  Coffee consumption and risk of hypertension: a dose-response meta-analysis of prospective studies.

Authors:  Lanfranco D'Elia; Ersilia La Fata; Ferruccio Galletti; Luca Scalfi; Pasquale Strazzullo
Journal:  Eur J Nutr       Date:  2017-12-08       Impact factor: 5.614

3.  UDP-glucuronosyltransferases mediate coffee-associated reduction of liver fibrosis in bile duct ligated humanized transgenic UGT1A mice.

Authors:  Steffen Landerer; Sandra Kalthoff; Christian P Strassburg
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

4.  Role of the Aryl Hydrocarbon Receptor (AhR) in Mediating the Effects of Coffee in the Colon.

Authors:  Robert S Chapkin; Laurie A Davidson; Hyejin Park; Un-Ho Jin; Yang-Yi Fan; Yating Cheng; Martha E Hensel; Kerstin K Landrock; Clinton Allred; Rani Menon; Cory Klemashevich; Arul Jayaraman; Stephen Safe
Journal:  Mol Nutr Food Res       Date:  2021-08-31       Impact factor: 6.575

5.  A Smartphone App (TRIANGLE) to Change Cardiometabolic Risk Behaviors in Women Following Gestational Diabetes Mellitus: Intervention Mapping Approach.

Authors:  Anne Lotte Potzel; Christina Gar; Jochen Seissler; Andreas Lechner
Journal:  JMIR Mhealth Uhealth       Date:  2021-05-11       Impact factor: 4.773

6.  Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial.

Authors:  Fangyuan Dong; Yan Zhang; Yiqin Huang; Yiqian Wang; Gansheng Zhang; Xiaona Hu; Jiaofeng Wang; Jie Chen; Zhijun Bao
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

Review 7.  Molecular Bases Underlying the Hepatoprotective Effects of Coffee.

Authors:  Federico Salomone; Fabio Galvano; Giovanni Li Volti
Journal:  Nutrients       Date:  2017-01-23       Impact factor: 5.717

8.  Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B.

Authors:  Alexander Hodge; Sarah Lim; Evan Goh; Ophelia Wong; Philip Marsh; Virginia Knight; William Sievert; Barbora de Courten
Journal:  Nutrients       Date:  2017-01-10       Impact factor: 5.717

Review 9.  Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

Authors:  Hannele Yki-Järvinen; Panu K Luukkonen; Leanne Hodson; J Bernadette Moore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-13       Impact factor: 46.802

10.  Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation.

Authors:  Jia-Hung Ye; Jung Chao; Ming-Ling Chang; Wen-Huang Peng; Hao-Yuan Cheng; Jiunn-Wang Liao; Li-Heng Pao
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.